Cybin Inc (CYBN)

Feb 10, 2025, 9:48 PM EST - 12 days ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 5 weeks ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 5 weeks ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 6 weeks ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 2 months ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 2 months ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 3 months ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 3 months ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 13, 2024, 7:30 AM EST - 3 months ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Oct 31, 2024, 7:30 AM EDT - 4 months ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Oct 24, 2024, 7:30 AM EDT - 4 months ago

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Oct 18, 2024, 2:30 PM EDT - 4 months ago

Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +

DAVA EQNR

Oct 15, 2024, 12:30 PM EDT - 4 months ago

Cybin: Top Value Psychedelic Stock

Oct 3, 2024, 7:30 AM EDT - 5 months ago

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

Oct 1, 2024, 7:30 AM EDT - 5 months ago

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Sep 27, 2024, 11:48 AM EDT - 5 months ago

Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”

Sep 24, 2024, 7:30 AM EDT - 5 months ago

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Sep 19, 2024, 5:38 PM EDT - 5 months ago

Cybin Provides Corporate Update on Upcoming Clinical Milestones

Sep 19, 2024, 8:00 AM EDT - 5 months ago

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale

Sep 19, 2024, 7:26 AM EDT - 5 months ago

Cybin Announces Completion of Previously Announced Share Consolidation

Sep 4, 2024, 7:55 AM EDT - 6 months ago

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 7:01 PM EDT - 6 months ago

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

Aug 27, 2024, 5:00 PM EDT - 6 months ago

Inovalis Real Estate Investment Trust Provides Supplemental Information in Connection With Its Upcoming Special Meeting of Unitholders to Be Held on September 4, 2024

V

Aug 13, 2024, 7:30 AM EDT - 6 months ago

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

Aug 12, 2024, 12:12 PM EDT - 6 months ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS MNMD

Aug 8, 2024, 7:36 AM EDT - 7 months ago

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Aug 7, 2024, 7:30 AM EDT - 7 months ago

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 8, 2024, 8:38 AM EDT - 8 months ago

A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update

Jun 26, 2024, 7:41 AM EDT - 8 months ago

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

Jun 25, 2024, 10:19 AM EDT - 8 months ago

Cilo Cybin becomes first medical cannabis company to list in South Africa

Jun 19, 2024, 7:30 AM EDT - 8 months ago

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 11, 2024, 7:30 AM EDT - 9 months ago

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development

May 29, 2024, 7:30 AM EDT - 9 months ago

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024

May 14, 2024, 7:30 AM EDT - 10 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 6, 2024, 8:32 AM EDT - 10 months ago

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

Apr 25, 2024, 7:30 AM EDT - 10 months ago

Cybin to Participate at the 27th Annual Milken Institute Global Conference

Apr 18, 2024, 7:30 AM EDT - 11 months ago

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

Apr 16, 2024, 7:30 AM EDT - 11 months ago

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

Apr 10, 2024, 7:30 AM EDT - 11 months ago

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Mar 19, 2024, 11:53 AM EDT - 1 year ago

Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million

Mar 18, 2024, 7:30 AM EDT - 1 year ago

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

Mar 15, 2024, 7:30 AM EDT - 1 year ago

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Announces Oversubscribed Private Placement of U.S. $150 Million

Mar 13, 2024, 6:00 AM EDT - 1 year ago

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Mar 12, 2024, 10:37 PM EDT - 1 year ago

Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003

Feb 27, 2024, 7:30 AM EST - 1 year ago

Cybin to Present at the TD Cowen 44th Annual Health Care Conference

Feb 14, 2024, 7:45 AM EST - 1 year ago

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

Feb 7, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program

Jan 23, 2024, 7:30 AM EST - 1 year ago

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder